ページ5 - 最高の肝癌医師 - トップ121名の医師

教育と上級トレーニング コース

• 1989年 - ヘブライ大学で高等医学教育を受ける;
• 1995年 - ハダッサ大学病院で内科および消化器科の研修を修了する。
• 2001年 - 2002年 - ニューヨークのシナイ医学部肝疾患部門でスコット・フリードマン教授とのインターンシップを行う。

現在、リファート・サファディ教授は肝疾患治療の分野で優れた専門家であり、体細胞移植センターの開発委員会のメンバーで、ハダッサ医療センター肝疾患ユニットの責任者です。教授は複数の国際肝研究協会のメンバーであり、専門分野で多くの論文を執筆しています。サファディ教授は、科学医学ジャーナル「Clinical Science」の編集委員会メンバーです。

リファート・サファディ氏は、多くの科学賞の受賞者です。特に彼は、mRNAを用いた肝線維化の免疫調節過程の研究でハダッサ賞を繰り返し受賞しています。同じ分野での業績により、教授はシャロン・ドンスキー賞およびイスラエル消化器病学と肝臓学協会の賞も受賞しました。

Tamar Jablonski-Perec is an oncologist at the Hadassah Medical Center who received her Doctor of Medical Sciences at the Hebrew University in Jerusalem and completed an internship at the renowned Sloan-Kettering Cancer Center in New York. Her key takeaways include:

• Head of Institute of Oncology in 1994
• Head of Breast Cancer Treatment Center in 1998
• Professor of the Department of Oncology at the Hebrew University in 2006
• Member of several international cancer communities
• Awarded a scholarship from the Hadassah Medical School

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Radiotherapist

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

Specializations

Cancer Surgery

Pancreatic Surgery

Bile Duct Surgery

Bariatric Metabolic Surgery

Oncological Surgery

Breast Surgery

Gastric cancer

Colon cancer

Thyroid Cancer

Obesity Surgery

Diabetes Surgeries

Dr. Lo Zhunchen is a highly experienced doctor who provides quality care at Fuda Hospital. He has a long history in the medical field, and his key takeaways include:

• Specializes in Internal Medicine, Respiratory Medicine, and Clinical Hematology
• Has over 20 years in medical practice
• Experienced in many medical treatments, including chemotherapy and radiotherapy
• Provides quality care with a focus on patient comfort and satisfaction
• Committed to evidence-based medicine and patient education

NUTRITION AND DIET SPECIALIST 

Ezgi Sevic graduated from Hacettepe University, Department of Nutrition and Dietetic as Honor Student. During her education, she conducted studies on “'The Effect of Hedonic Eating Behavior on Obesity', 'Total Parenteral Nutrition in Children' and 'The Relationship Between Insulin Resistance and Obesity'.” During her education, she took part in the field in studies on determining the nutritional status of the society. She worked as intern dietitian in Hospitals of Hacettepe University (Oncology Hospital, Adults Hospital, İhsan Doğramacı Child Hospital), Dışkapı Yıldırım Beyazıt Training and Research Hospital and many Community Health Centres. 
She worked in Izmir Private Ekol Hospital. She successfully completed the 'Bariatric Nutrition Course' and the 'Innovations in Obesity Course'. She has participated in many training and seminar programs in her field. 

Interests: Post- Metabolic and Bariatric Surgery Nutrition, the Nutrition in Chronicle Diseases, Nutrition in Individuals with Diabetes, Nutrition in Cancer, Nutrition in Congenital Metabolic Diseases, Food Intolerances, Body Weight Control, Child and Adolescent Nutrition, Nutrition in Old Age, Nutrition in Pregnancy and Lactation.

Dietit. Ezgi Sevic knows advanced English. 

この医師は腫瘍学の専門家であり、肝臓、胆嚢、胃、膵臓、腸管、および乳がんの治療を専門としています。この医師は、Fuda Hospitalで腫瘍専門医としての豊富な経験を持ち、タイのBumrungrad International HospitalおよびRoyal Siriraj Hospitalでも勤務しています。さらに、この医師は中国抗癌協会のメンバーであり、がん治療と研究の進展に対するコミットメントを示しています。

Dr. Wang Jiannan is an experienced Oncologist with 43 years of experience, currently working at Fuda Cancer Hospital. Here are some of his key takeaways:

• 43 years experience
• Specialty in Oncology
• Currently working at Fuda Cancer Hospital

この医師は、消化器がん、肺がん、婦人科腫瘍の治療において豊富な経験を持っています。彼女は悪性腫瘍性疾患の診断と複雑なケアの専門家として認められています。

悪性腫瘍治療に関する30以上の国内外の科学論文の著者であり、European Society for Medical Oncologyおよびその他の専門協会のメンバーです。

1993年にイスタンブール大学を卒業し、2010年に准教授に昇進し、現在はLIV Hospitalで主要な腫瘍専門医として働いています。彼女の経歴には、Taksim Training and Research Hospital、Kayseri Hospital、Istanbul Hospital、Neolife Medical Centerでの職務が含まれます。

Marmara University Faculty of Medicine, Department of Radiation Oncology Specialization training: 2012 -2016

Marmara University Faculty of Medicine (English) Undergraduate: 2004-2011

Sixteen Numbered Shirvan School (Azerbaijan) High School: 1998 -2004

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Surgeon, oncosurgeon, specialist in the treatment of gastrointestinal tract

Dr. Bernd Hertenstein is a renowned Clinical Oncologist with 32 years of experience in providing chemotherapy and radiotherapy to cancer patients.

• Tumour Marker Blood Test
• Bone Marrow Transplant
• Autologous bone marrow transplantation
• Allogenic bone marrow transplantation from a related donor
• Allogenic bone marrow transplantation from an unrelated donor
• Radiofrequency ablation of the liver
• Chemotherapy for liver cancer
• Chemoembolization of the liver
• Chemotherapy for breast cancer
• Leukemia chemotherapy
• Stem cell transplantation
• Contributor to numerous publications

教育経験

• アメリカン・ロバート・カレッジ、イスタンブル、トルコ (1973-1977)
• ウルダ大学医学部、医学のディプロマ、ブルサ、トルコ (1983)
• 国立がん研究所、N.C.I、N.I.H 研究奨学金、「職業曝露とがんリスク」 ベセスダ、MD、米国 (1989)
• オンコロジー・核医学センター、 放射線腫瘍学研修医、イスタンブル、トルコ 専門認定証 (1990)
• トーマス・ジェファーソン大学、博士後研究フェローシップ、サーモラジオセラピー学部放射線腫瘍学科 フィラデルフィア、PA、米国 (1990-1994)

経験

• パザルヨル・メディカル・ハウス、義務奉仕 イスピル、エルズルム、トルコ (1985-1986)
• 国立がん研究所、N.C.I、N.I.H 研究奨学金「職業曝露とがんリスク」 ベセスダ、MD、米国 (1989)
• オンコロジー・核医学センター、放射線腫瘍学研修医 イスタンブル、トルコ 専門認定証 (1990)
• トーマス・ジェファーソン大学、博士後研究フェローシップ サーモラジオセラピー学部放射線腫瘍学科 フィラデルフィア、PA、米国 (1990-1994)
• ウルダ大学医学部 (1991-2005) 教授 (1999-2005) & 学部長 (1994-2005) 放射線腫瘍学科 ブルサ、トルコ
• ウルダ大学医学部、学部認定コーディネーター ブルサ、トルコ (2001-2004)
• アナドルメディカルセンター、教授 & 放射線腫瘍学科長 イスタンブル、トルコ (2004-2017)
• アナドルメディカルセンター、腫瘍科学コーディネーター イスタンブル、トルコ (2011-2017)
• ジェイラン国際病院、腫瘍科学ディレクター ブルサ、トルコ (2017-2018)
• メディカナ・ブルサ病院、腫瘍科学ディレクター ブルサ、トルコ (2018-現在)